
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 â¥50% Expression in Lung Adenocarcinoma
Keywords: Lung cancer; PD-L1; PD-1; Pembrolizumab; EGFR; ALK;